Attention Deficit Hyperactivity Disorder Stocks List

Recent Signals

Date Stock Signal Type
2021-04-20 COLL Bollinger Band Squeeze Range Contraction
2021-04-20 COLL 20 DMA Resistance Bearish
2021-04-20 DRRX Lower Bollinger Band Walk Weakness
2021-04-20 KMPH Bollinger Band Squeeze Range Contraction
2021-04-20 LLY Upper Bollinger Band Walk Strength
2021-04-20 LLY Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-20 LLY Shooting Star Candlestick Bearish
2021-04-20 LLY Doji - Bearish? Reversal
2021-04-20 LLY Lizard Bearish Bearish Day Trade Setup
2021-04-20 NLSP Stochastic Buy Signal Bullish
2021-04-20 NLSP Lower Bollinger Band Walk Weakness
2021-04-20 SUPN NR7 Range Contraction
2021-04-20 SUPN Calm After Storm Range Contraction
2021-04-20 SUPN Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-04-20 VLON NR7 Range Contraction
2021-04-20 VLON Narrow Range Bar Range Contraction
2021-04-20 VLON Stochastic Reached Oversold Weakness

Recent News for Attention Deficit Hyperactivity Disorder Stocks

Date Stock Title
Apr 20 SUPN Supernus Pharmaceuticals (SUPN) Investor Presentation - Slideshow
Apr 20 LLY Lilly, Incyte's second baricitinib study shows improvement in hair regrowth in alopecia areata patients
Apr 20 LLY Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Apr 19 LLY Large NIH-funded study to explore repurposed drugs for mild-to-moderate COVID-19
Apr 19 LLY Eli Lilly And Incyte’s Baricitinib Fails To Meet Endpoint In Phase 3 COVID-19 Trial
Apr 19 LLY Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo
Apr 18 LLY AACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapy
Apr 16 LLY Lilly and Incyte's baricitinib fails to meet main goal in late-stage COVID-19 trial
Apr 16 LLY WHO says global COVID-19 cases nearly doubled in last two months, making vaccine drive more urgent than ever
Apr 16 LLY Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU
Apr 16 LLY UPDATE 2-Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab
Apr 16 LLY Lilly requests withdrawal of emergency use nod of bamlanivimab alone in COVID-19
Apr 16 LLY Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development
Apr 16 LLY Eli Lilly asks FDA to revoke EUA for COVID antibody treatment alone to speed transition to combination therapy
Apr 16 LLY Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Apr 16 LLY Premarket Movers Friday - DraftKings, Morgan Stanley, Splunk
Apr 15 COLL Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
Apr 15 LLY Merck hurt by another setback in its battle against COVID-19
Apr 14 LLY Eli Lilly and SciNeuro Pharmaceuticals ink exclusive license agreement
Apr 14 NLSP 22 Stocks Moving in Wednesday's Pre-Market Session

Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity, or difficulty controlling behavior which is not appropriate for a person's age. The symptoms appear before a person is twelve years old, are present for more than six months, and may cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention span for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the exact cause is unknown in the majority of cases. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015 it is estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults inner restlessness rather than hyperactivity may occur. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normative behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend that medications and behavioral therapy be used together as a first-line therapy, except in preschool-aged children. Stimulant medication therapy is not recommended as a first-line therapy in preschool-aged children in either guideline. Treatment with stimulants is effective for at least 14 months; however, their long term effectiveness is unclear. Adults often develop coping skills which make up for some or all of their impairments.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention-deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

More about Attention Deficit Hyperactivity Disorder
Browse All Tags